Clinical and Experimental Pediatrics

대한소아청소년과학회 (The Korean Pediatric Society)
권호 표지
DOI QR코드

DOI QR Code

Changes in age-specific seroprevalence of Japanese encephalitis virus and impact of Japanese encephalitis vaccine in Korea

  • Kwak, Byung Ok (Department of Pediatrics, Hallym University Kangnam Sacred Heart Hospital) ;
  • Hong, Young Jin (Department of Pediatrics, Inha University School of Medicine) ;
  • Kim, Dong Hyun (Department of Pediatrics, Inha University School of Medicine)
  • 투고 : 2020.12.07
  • 심사 : 2021.09.11
  • 발행 : 2022.03.15
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

The Japanese encephalitis (JE) virus is the leading cause of vaccine-preventable encephalitis in Asia. Since the introduction of a universal JE vaccination program and urbanization of Korea, the incidence of JE has dramatically decreased in Korea. However, recent JE cases have occurred, predominantly among unvaccinated adults and with a shift in age distribution. Here we aimed to review the changes in age-specific JE seroprevalence over time and discuss the implications of JE vaccination programs in Korea. Following the last epidemic in 1982-1983, mandatory vaccination for all children aged 3-15 years was conducted annually until 1994. However, JE has reemerged, predominantly affecting unvaccinated adults aged 40 years or older and demonstrating a shift in age distribution toward older populations. The age-specific seroprevalence of the JE virus in Korea has changed noticeably over time. Seropositivity in children and adolescents increased from 10%-59% in the 1970s to 90%-92% in the 1980s after the implementation of the JE vaccination program and increased further to 98% in 2012. No age-specific difference in the seroprevalence of JE was found, and appropriate levels of immunity to JE were maintained for all age groups. Continuous surveillance of the seroprevalence of JE is essential to establish a proper immunization policy in Korea.

키워드

과제정보

The authors would like to thank all the members of the Korean Society of Pediatric Infectious Diseases.

참고문헌

  1. Halstead SB, Hills SL, Dubischar K. Japanese encephalitis vaccines. In: Plotkin SA, Orentein WA, Offit PA, Edwards KM, editors. Plotkin's vaccines. 7th ed. Philadelphia (PA): Elsevier, 2018:511-48.
  2. Solomon T. Control of Japanese encephalitis-within our grasp? N Engl J Med 2006;355:869-71. https://doi.org/10.1056/NEJMp058263
  3. Heffelfinger JD, Li X, Batmunkh N, Grabovac V, Diorditsa S, Liyanage JB, et al. Japanese Encephalitis Surveillance and Immunization - Asia and Western Pacific Regions, 2016. MMWR Morb Mortal Wkly Rep 2017;66:579-83. https://doi.org/10.15585/mmwr.mm6622a3
  4. Sohn YM. Japanese encephalitis immunization in South Korea: past, present, and future. Emerg Infect Dis 2000;6:17-24. https://doi.org/10.3201/eid0601.000103
  5. Sabin AB, Schlesinger RW. Japanese B encephalitis in American soldiers in Korea. Am J Hyg 1947;46:356-75.
  6. Lee EJ, Cha GW, Ju YR, Han MG, Lee WJ, Jeong YE. Prevalence of neutralizing antibodies to Japanese encephalitis virus among high-risk age groups in South Korea, 2010. PLoS One 2016;11:e0147841. https://doi.org/10.1371/journal.pone.0147841
  7. Lee DW, Choe YJ, Kim JH, Song MK, Cho H, Bae GR, et al. Epidemiology of Japanese encephalitis in South Korea, 2007-2010. Int J Infect Dis 2012;16:448-52.
  8. Campbell GL, Hills SL, Fischer M, Jacobson JA, Hoke CH, Hombach JM, et al. Estimated global incidence of Japanese encephalitis: a systematic review. Bull World Health Org 2011;89:766-74, 774A-774E. https://doi.org/10.2471/BLT.10.085233
  9. Simon-Loriere E, Faye O, Prot M, Casademont I, Fall G, Fernandez-Garcia MD, et al. Autochthonous Japanese encephalitis with yellow fever coinfection in Africa. N Engl J Med 2017;376:1483-5. https://doi.org/10.1056/NEJMc1701600
  10. Sunwoo JS, Jung KH, Lee ST, Lee SK, Chu K. Reemergence of Japanese encephalitis in South Korea, 2010-2015. Emerg Infect Dis 2016;22:1841-3. https://doi.org/10.3201/eid2210.160288
  11. Arai S, Matsunaga Y, Takasaki T, Tanaka-Taya K, Taniguchi K, Okabe N, et al. Vaccine preventable diseases surveillance program of Japan. Japanese encephalitis: surveillance and elimination effort in Japan from 1982 to 2004. Jpn J Infect Dis 2008;61:333-8.
  12. Hsu LC, Chen YJ, Hsu FK, Huang JH, Chang CM, Chou P, et al. The incidence of Japanese encephalitis in Taiwan - a population-based study. PLoS Negl Trop Dis 2014;8;e3030. https://doi.org/10.1371/journal.pntd.0003030
  13. Tseng HF, Tan HF, Chang CK, Huang WL, Ho WC. Seroepidemiology study of Japanese encephalitis neutralizing antibodies in southern Taiwan: a comparative study between urban city and country townships. Am J Infect Control 2003;31:435-40. https://doi.org/10.1067/mic.2003.73
  14. Korea Centers for Disease Control and Prevention. Infectious diseases surveillance yearbook 2019. Cheongju (Korea): Korea Centers for Disease Control and Prevention, 2020.
  15. Yun KW, Lee HJ, Park JY, Cho HK, Kim YJ, Kim KH, et al. Long-term immunogenicity of an initial booster dose of an inactivated, Vero cell culture-derived Japanese encephalitis vaccine (JE-VC) and the safety and immunogenicity of a second JE-VC booster dose in children previously vaccinated with an inactivated, mouse brain-derived Japanese encephalitis vaccine. Vaccine 2018;36:1398-404. https://doi.org/10.1016/j.vaccine.2018.01.075
  16. The Korean Pediatric Society. Japanese encephalitis vaccines. In: Kim JH, editor. Immunization guideline. 9th ed. Seoul (Korea): The Korean Pediatric Society, 2018:186-202.
  17. Cha SH. The history of vaccination and current vaccination policies in Korea. Clin Exp Vaccin Res 2012;1:3-8. https://doi.org/10.7774/cevr.2012.1.1.3
  18. Choe YJ, Taurel AF, Nealon J, Seo HS, Kim HS. Systematic review of seroepidemiological studies on Japanese encephalitis in the Republic of Korea. Int J Infect Dis 2018;67:14-9. https://doi.org/10.1016/j.ijid.2017.11.023
  19. Kwak BO, Kwon YS, Hong YJ, Nahm CH, Jang W, Uh Y, et al. Seroprevalence of neutralizing antibodies against Japanese encephalitis virus among adolescents and adults in Korea: a prospective multicenter study. Vaccines (Basel) 2020;8:328. https://doi.org/10.3390/vaccines8020328
  20. Deuel RE Jr, Barwell MB, Matumoto M, Sabain AB. Status and significance of inapparent infection with virus of Japanese B encephalitis in Korean and Okinawa in 1946. Am J Hyg 1950;51:13-20.
  21. Kim KH. Recent epidemiological features of Japanese encephalitis in the Republic of Korea. Korean J Infect Dis 1974;6:83-8.
  22. Kim SO, Lee YJ, Jung BK, Lee HW. The distribution of hemagglutination inhibition antibody for Japanese encephalitis in residents of Seoul areas. Choeshin Ui-hak 1976;19:21-6.
  23. Lee YT, Lee CH. Serological study on Japanese encephalitis in Koreans and fowls, 1975. Korean J Infect Dis 1976;8:75-82.
  24. Lee YT, Lee CH. The distribution of hemagglutination inhibition antibodies for Japanese encephalitis virus against the Koreas 1976. J Korean Soc Microbiol 1977;12:51-6.
  25. Lee CH, Ko KK. The distribution of hemagglutination inhibition antibodies for Japanese encephalitis virus in Korea (1977, 1978). Choeshin Ui-hak 1979:113-9.
  26. Lee CH, Lee YT, Ko KJ, Moon KS, Kim OJ. The distribution of hemagglutination inhibition antibodies for Japanese encephalitis virus in Koreans 1979. Korean J Virol 1980;10:65-9.
  27. Lee YT, Youm BJ. A hemagglutination inhibition antibody test for Japanese encephalitis virus among the Koreans, 1984-1985. Korean J Virol 1985;15:1-9.
  28. Abe M, Okada K, Hayashida K, Matsuo F, Shiosaki K, Miyazaki C, et al. Duration of neutralizing antibody titer after Japanese encephalitis vaccination. Microbiol Immunol 2007;51:609-16. https://doi.org/10.1111/j.1348-0421.2007.tb03947.x
  29. Lee HJ, Min KI, Park KH, Choi HJ, Kim MK, Ahn CY, et al. Comparison of JEV neutralization assay using pseudotyped JEV with the conventional plaque-reduction neutralization test. J Microbiol 2014;52:435-40. https://doi.org/10.1007/s12275-014-3529-y
  30. Kwak BO, Kwon YS, Hong YJ, Shin SH, Eun BW, Ahn YM, et al. Immunogenicity and safety of the third booster dose of the inactivated Japanese encephalitis vaccine in Korean. Vaccine 2021;39:1929-32. https://doi.org/10.1016/j.vaccine.2021.02.076